The central government has constituted an inter‑ministerial committee to design and oversee the proposed Biopharma Shakti Hub scheme. The ₹10,000‑crore initiative was announced in the Union Budget and seeks to position India as a global manufacturing base for next‑generation biological medicines.
The move brings together regulators, research bodies, and policy makers under a single framework. It reflects a coordinated push to strengthen the domestic biopharmaceutical ecosystem.
The panel has been formed as an inter‑ministerial committee tasked with preparing and monitoring the Biopharma Shakti Hub scheme. It is headed by Manoj Joshi, Secretary of the Department of Pharmaceuticals.
Members include representatives from the Ministry of Health and Family Welfare, the Department of Biotechnology, the Indian Council of Medical Research, and the Central Drugs Standard Control Organisation. The composition signals an integrated approach covering research, regulation, and manufacturing.
The Biopharma Shakti Hub has been conceived to establish India as a global manufacturing hub for advanced biological medicines. The scheme aims to support the development and large‑scale production of next‑generation biologics, including complex therapies.
By aligning policy, regulatory oversight, and scientific capabilities, the initiative seeks to address existing gaps across the value chain. The ₹10,000‑crore allocation underlines the scale of ambition attached to the programme.
The proposed scheme is positioned as a natural progression of the National Biopharma Mission launched in 2017. That Cabinet‑approved programme was implemented under the Department of Biotechnology and partly funded by the World Bank.
It focused on strengthening translational research, product development, and collaboration between academia and industry. Shared infrastructure, clinical trial networks, and technology transfer offices were key components of that earlier mission.
The inclusion of ICMR and CDSCO alongside policy departments highlights the equal emphasis on scientific research and regulatory readiness. The scheme is expected to support innovation while ensuring regulatory pathways are clearly defined.
Manufacturing capacity expansion is intended to be aligned with evolving clinical and compliance standards. This coordinated structure is designed to shorten development cycles and enable scalable production of complex biologics.
Read More: Essential Drug Prices May Rise 10–20% Temporarily Amid Supply Disruptions.
The formation of the inter‑ministerial panel marks a formal step towards operationalising the Biopharma Shakti Hub scheme. With coordinated oversight across multiple institutions, the initiative seeks to strengthen India’s position in the global biopharmaceutical landscape.
Its linkage with the National Biopharma Mission provides an institutional foundation for execution. Overall, the scheme reflects a structured policy effort to integrate research, regulation, and manufacturing under a single strategic framework.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 30, 2026, 5:16 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
